| Type I interferon inhibitor anifrolumab in active system... |
51 |
| Management of IgG4-related disease |
16 |
| Low-dose interleukin-2 therapy in refractory systemic lu... |
9 |
| Risk factors for dislocation after primary total hip rep... |
8 |
| Probiotic treatment using a mix of three Lactobacillus s... |
7 |
| IgG4-related disease in the Japanese population: a genom... |
7 |
| Symptom-based stratification of patients with primary Sj... |
6 |
| Definitions of remission in systemic lupus erythematosus... |
6 |
| The effects of canagliflozin on gout in type 2 diabetes:... |
6 |
| Comparative efficacy and safety of treatments for second... |
5 |
